NCCN-IPI: Enhanced granular scoring for DLBCL treated with immunochemotherapy.
Age at Diagnosis
Serum LDH (Normalized Ratio)
Total NCCN-IPI Score
Risk Category
Estimated 5-y Overall Survival: 96%
Verified
Last Review: 2026-07-17
| Parameter | Criteria | Points |
|---|---|---|
| Age | 41 - 60 | 1 |
| 61 - 75 | 2 | |
| > 75 | 3 | |
| LDH | 1x - 3x ULN | 1 |
| > 3x ULN | 2 | |
| Ann Arbor Stage | III or IV | 1 |
| Extranodal Disease | BM, CNS, Liver/Lung, or GI | 1 |
| Performance Status | ECOG ≥ 2 | 1 |
| Score | Risk Group | Estimated 5-y OS |
|---|---|---|
| 0 - 1 | Low | 96% |
| 2 - 3 | Low-Intermediate | 82% |
| 4 - 5 | High-Intermediate | 64% |
| ≥ 6 | High | 33% |
Zhou Z et al. • Blood. 2014;123(6):837-42.
View SourceLast Comprehensive Review: 2026-07-17
Clinical Context
We think this has broad domain relevance to NCCN-IPI for DLBCL.
Clinical Context
We think this has broad domain relevance to NCCN-IPI for DLBCL.
Clinical Context
We think this has broad domain relevance to NCCN-IPI for DLBCL.
